Insufficienza epatica cronica

Responsabile scientifico/Coordinatore – Prof. Paolo Caraceni

Attività di ricerca

  • Cirrosi epatica
  • Complicanze della cirrosi (ascite, danno renale acuto (AKI), insufficienza epatica acuta su cronica (ACLF), encefalopatia epatica, infezioni batteriche)
  • Trattamento eziologico della cirrosi scompensata
  • Trattamento patogenetico della cirrosi scompensata (albumina umana, statine, vasocostrittori)
  • Alterazioni dell’albumina nelle epatopatie in stadio avanzato
  • Sistemi prognostici nel cirrotico con emorragia digestiva
  • Danno epatico da farmaci
  • Trapianto di fegato

Membri del gruppo

Maurizio Baldassarre

Cat. D - area tecnica, tecnico - scientifica ed elaborazione dati

Mauro Bernardi

Professore emerito

Professore a contratto a titolo gratuito

Maurizio Biselli

Ricercatore confermato

Paolo Caraceni

Professore associato

Marina Naldi

Ricercatrice a tempo determinato tipo b) (senior)

Manuel Tufoni

Dottorando

Giacomo Zaccherini

Assegnista di ricerca

Altri membri

Dott.ssa Martina Gagliardi (Borsista)

Collaborazioni nazionali e internazionali 

 

             - European Foundation for the Study of Chronic Liver Failure (EF-CLIF) - Spain

            - University College of London (UCL) - United Kingdom

            - Hopital Clinic, Institut d’Investigacions Biomediques August PI I Sunyer   (IDIBAPS), Universitat de Barcellona - Spain

            - Centre de Recherche sur l’Inflammation (CRI), INSERM, Université Paris, Diderot, Paris - France

Produzione scientifica 

  1. Biselli M, Gramenzi A, Lenzi B, Dall'Agata M, Pierro ML, Perricone G, Tonon M, Bellettato L, D'Amico G, Angeli P, Boffelli S, Bonavita ME, Domenicali M, Caraceni P, Bernardi M, Trevisani F. Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. Clin Gastroenterol Hepatol. 2019 Jun;17(7):1388-1397.
  2. Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol. 2018 Jul 19.
  3. Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Fagiuoli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, Cacciola I, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. 2018 Jun 16;391(10138):2417-2429.
  4. Caraceni P, Pavesi M, Baldassarre M, Bernardi M, Arroyo V. The use of human albumin in patients with cirrhosis: a European survey. Expert Rev Gastroenterol Hepatol. 2018 Jun;12(6):625-632.
  5. Piano S, Bartoletti M, Tonon M, Baldassarre M, Chies G, Romano A, Viale P, Vettore E, Domenicali M, Stanco M, Pilutti C, Frigo AC, Brocca A, Bernardi M, Caraceni P, Angeli P. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut. 2018 Oct;67(10):1892-1899
  6. Martini S, Donato MF, Mazzarelli C, Rendina M, Visco-Comandini U, Filì D, Gianstefani A, Fagiuoli S, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Carrai P, Caraceni P; ITACOPS study group. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. Liver Int. 2018 Apr;38(4):733-741.
  7. Naldi M, Baldassarre M, Domenicali M, Bartolini M, Caraceni P. Structural and functional integrity of human serum albumin: Analytical approaches and clinical relevance in patients with liver cirrhosis. J Pharm Biomed Anal. 2017 Sep 10;144:138-153.
  8. Baldassarre M, Domenicali M, Naldi M, Laggetta M, Giannone FA, Biselli M, Patrono D, Bertucci C, Bernardi M, Caraceni P. Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule. Sci Rep. 2016 Oct 26;6:35987.
  9. Naldi M, Baldassarre M, Domenicali M, Giannone FA, Bossi M, Montomoli J, Sandahl TD, Glavind E, Vilstrup H, Caraceni P, Bertucci C. Mass spectrometry characterization of circulating human serum albumin microheterogeneity in patients with alcoholic hepatitis. J Pharm Biomed Anal. 2016 Apr 15;122:141-7.
  10. Caraceni P, Angeli P, Prati D, Bernardi M; Italian Association for the Study of the Liver (AISF), Liumbruno GM, Bennardello F, Piccoli P, Velati C; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfus. 2016 Jan;14(1):8-22.
  11. Giannone FA, Domenicali M, Baldassarre M, Bartoletti M, Naldi M, Laggetta M, Bertucci C, Colecchia A, Viale P, Bernardi M, Caraceni P. Ischaemia-modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis.Liver Int. 2015 Nov;35(11):2425-32.
  12. Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, Moore N, De Ponti F. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015 Aug;80(2):285-93.
  13. Biselli M, Dall'Agata M, Gramenzi A, Gitto S, Liberati C, Brodosi L, Ravaioli M, Gambato M, Montalti R, Pinna AD, Burra P, Gerunda GE, Cillo U, Andreone P, Bernardi M. A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. Liver Int. 2015 Jan;35(1):184-91.
  14. Domenicali M, Baldassarre M, Giannone FA, Naldi M, Mastroroberto M, Biselli M, Laggetta M, Patrono D, Bertucci C, Bernardi M, Caraceni P. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology. 2014 Dec;60(6):1851-60.